Loading...
SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil plus bevacizumab (bev) versus capecitabine plus bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
Andre, T Saunders, Mark P Kanehisa, A Gandossi, E Fougeray, R Causse-Amellal, N Falcone, A
Andre, T
Saunders, Mark P
Kanehisa, A
Gandossi, E
Fougeray, R
Causse-Amellal, N
Falcone, A
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2019
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Andre T, Saunders MP, Kanehisa A, Gandossi E, Fougeray R, Causse-Amellal N, et al. 665TiP SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy. Annals of Oncology. 2019;30(Supplement_5):250.